Bile duct cancer combo trial halted early
NCT ID NCT05998447
First seen Dec 16, 2025 · Last updated May 02, 2026 · Updated 16 times
Summary
This study tested a new drug combination (GEN-001 plus pembrolizumab) in 10 adults with advanced bile duct cancer that had stopped responding to standard treatments. The goal was to see if the combination was safe and could shrink tumors. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ajou University Medical Center
Suwon, 16499, South Korea
-
Asan Medical Center
Seoul, Seoul, 05505, South Korea
-
Korea University Guro Hospital
Seoul, Seoul, 08308, South Korea
-
Samsung Medical Center.
Seoul, Seoul, 06351, South Korea
-
Seoul National University Hospital
Seoul, Seoul, 03080, South Korea
-
Severance Hospital
Seoul, Seoul, 03722, South Korea
Conditions
Explore the condition pages connected to this study.